Findings from the current study demonstrate that over half of chronic HF patients in the DIG trial had severe and more advanced disease as evidenced by the presence of NYHA III–IV symptoms, LVEF <25%, ...

KAIMRC researchers have shown that a drug, commonly used to treat various types of heart failure, appears to increase mortality risk in certain groups of patients when it is used in place of current ...

Three independent pharmacokinetic studies were conducted to assess potential drug interactions between argatroban administered concomitantly with commonly prescribed drugs in the hospital setting that ...

Please provide your email address to receive an email when new articles are posted on . At 6 months, quality of life in patients with permanent atrial fibrillation and symptomatic HF treated with ...

The heart drug digoxin could potentially be combined with existing cancer therapies to prevent the spread of tumors, an early trial suggests. But questions remain. When you purchase through links on ...

Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...

Madrid, Spain – 29 August 2025: Digitoxin reduced the risk of a composite of all-cause death and hospitalisation for worsening heart failure (HF) among patients with advanced HF and a reduced ejection ...

MADRID, Spain—Adding digitoxin, a cardiac glycoside, to contemporary guideline-directed medical therapy (GDMT) improves clinical outcomes in patients who have heart failure with reduced ejection ...